-
1.发明授权Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies 有权使用血浆蛋白质组学模式进行诊断，分类，对治疗反应的预测和临床行为，治疗分层和监测血液恶性肿瘤的疾病公开(公告)号：US08097468B2
公开(公告)日：2012-01-17
申请号：US12582998
申请日：2009-10-21
CPC分类号： G01N33/6851 , G01N33/57426 , G01N33/6803 , G01N33/6848 , G01N2800/52 , Y10T436/24 , Y10T436/25 , Y10T436/25625
摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。
-
2.发明申请Actin proteins as biomarkers for indication and targeting of resistance and sensitivity to an Abl kinase inhibitor in patients with chronic myelogenous leukemia 审中-公开肌动蛋白作为生物标志物，用于指示和靶向慢性粒细胞性白血病患者的Abl激酶抑制剂的抗性和敏感性公开(公告)号：US20080108549A1
公开(公告)日：2008-05-08
申请号：US11731019
申请日：2007-03-29
CPC分类号： G01N33/6887 , A61K38/012 , C07K14/4716 , G01N2333/4712
摘要： The invention relates to 5 identified protein biomarkers, gamma- and beta-Actin proteins, for screening, diagnosis, drug targeting, and drug design for resistance of cancer to an Ab1 kinase inhibitor. The method is based on the use of two-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in bone marrow aspirate samples, taken from patients at time of diagnosis of Chronic Myelogenous Leukemia (CML), the quantitation of 5 protein spots identified as beta- and/or gamma-Actin proteins, to differentiate between patients who will respond to or resist treatment when the patients are subsequently treated with an Ab1 kinase inhibitor.
摘要翻译： 本发明涉及用于筛选，诊断，药物靶向和针对Ab1激酶抑制剂的抗癌药物设计的5种鉴定的蛋白质生物标志物γ-和β-肌动蛋白。 该方法基于使用二维（2D）凝胶电泳分离在诊断为慢性骨髓性白血病（CML）时从患者获取的骨髓抽吸样品中发现的蛋白质的复杂混合物，定量5种蛋白质 被鉴定为β-和/或γ-肌动蛋白的斑点，以区分当患者随后用Ab1激酶抑制剂治疗时将响应或抵抗治疗的患者。
-
公开(公告)号：US08563323B2
公开(公告)日：2013-10-22
申请号：US13325986
申请日：2011-12-14
CPC分类号： G01N33/6851 , G01N33/57426 , G01N33/6803 , G01N33/6848 , G01N2800/52 , Y10T436/24 , Y10T436/25 , Y10T436/25625
摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
-
公开(公告)号：US20130217710A1
公开(公告)日：2013-08-22
申请号：US13883374
申请日：2011-11-04
申请人： Manuel Carlos Alves-Aivado , Gautam Borthakur , Tapan M. Kadia , Hagop M. Kantarjian , Sylvie Laquerre
发明人： Manuel Carlos Alves-Aivado , Gautam Borthakur , Tapan M. Kadia , Hagop M. Kantarjian , Sylvie Laquerre
IPC分类号： A61K31/519 , A61K31/436 , A61K45/06 , A61K31/506
CPC分类号： A61K31/519 , A61K31/192 , A61K31/436 , A61K31/44 , A61K31/506 , A61K31/7068 , A61K45/06 , A61K2300/00
摘要： Methods are provided for treating a human having cancer comprising detecting at least one mutation in a Ras protein or a gene encoding at least one Ras protein from at least one tumor cell from said human and treating said human having at least one mutation in at least one Ras protein or a gene encoding at least one Ras protein with a pharmaceutical composition comprising at least one MEK inhibitor comprising a compound of Structure (I): or a pharmaceutically acceptable salt or solvate thereof.
摘要翻译： 提供了用于治疗患有癌症的人的方法，包括从所述人的至少一个肿瘤细胞检测Ras蛋白中的至少一个突变或编码至少一种Ras蛋白的基因，并在至少一种 Ras蛋白或编码至少一种Ras蛋白的基因与包含至少一种包含结构（I）的化合物的MEK抑制剂或其药学上可接受的盐或溶剂合物的药物组合物。
-
5.发明申请公开(公告)号：US20100063747A1
公开(公告)日：2010-03-11
申请号：US12582998
申请日：2009-10-21
IPC分类号： G06F19/00
CPC分类号： G01N33/6851 , G01N33/57426 , G01N33/6803 , G01N33/6848 , G01N2800/52 , Y10T436/24 , Y10T436/25 , Y10T436/25625
摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。
-
6.发明申请Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies 有权使用血浆蛋白质组学模式进行诊断，分类，治疗反应预测和临床行为，治疗分层和监测血液恶性肿瘤疾病公开(公告)号：US20120145891A1
公开(公告)日：2012-06-14
申请号：US13325986
申请日：2011-12-14
IPC分类号： H01J49/26
CPC分类号： G01N33/6851 , G01N33/57426 , G01N33/6803 , G01N33/6848 , G01N2800/52 , Y10T436/24 , Y10T436/25 , Y10T436/25625
摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。
-
7.发明授权Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies 有权使用血浆蛋白质组学模式进行诊断，分类，对治疗反应的预测和临床行为，治疗分层和监测血液恶性肿瘤的疾病公开(公告)号：US07622306B2
公开(公告)日：2009-11-24
申请号：US11110374
申请日：2005-04-20
CPC分类号： G01N33/6851 , G01N33/57426 , G01N33/6803 , G01N33/6848 , G01N2800/52 , Y10T436/24 , Y10T436/25 , Y10T436/25625
摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
